

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 7/22, 7/16	A1	(11) International Publication Number: WO 95/17159 (43) International Publication Date: 29 June 1995 (29.06.95)
(21) International Application Number: PCT/US94/14757 (22) International Filing Date: 21 December 1994 (21.12.94) (30) Priority Data: 08/171,576 22 December 1993 (22.12.93) US (71) Applicant: THE PROCTER & GAMBLE COMPANY [US/US]; One Procter & Gamble Plaza, Cincinnati, OH 45202 (US). (72) Inventor: HALL, William, Gerald; 1745 Chase Avenue, Cincinnati, OH 45223 (US). (74) Agents: REED, T., David et al.; The Procter & Gamble Company, 5299 Spring Grove Avenue, Cincinnati, OH 45217 (US).		(81) Designated States: BR, CN, JP, PL, RU, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: CONCENTRATED MOUTHRINSE FOR EFFICIENT DELIVERY OF ANTIMICROBIALS (57) Abstract Concentrated mouthrinse, methods of use and methods of manufacturing the mouthrinse for efficient delivery of cationic and water-insoluble noncationic antimicrobials wherein the composition is concentrated and substantially free of non-cationic surfactants.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LV	Latvia	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
CZ	Czech Republic	LV	Latvia	TJ	Tajikistan
DE	Germany	MC	Monaco	TT	Trinidad and Tobago
DK	Denmark	MD	Republic of Moldova	UA	Ukraine
ES	Spain	MG	Madagascar	US	United States of America
FI	Finland	ML	Mali	UZ	Uzbekistan
FR	France	MN	Mongolia	VN	Viet Nam
GA	Gabon				

CONCENTRATED MOUTH RINSE FOR EFFICIENT DELIVERY OF ANTIMICROBIALS

TECHNICAL FIELD

5 The present invention relates to a concentrated mouthrinse and methods of use and methods of making the same, wherein there is an efficient delivery of antimicrobials to the oral cavity thereby reducing oral bacteria, mouth malodor and further promoting oral health.

BACKGROUND OF THE INVENTION

10 Plaque is an organic mixture of living bacteria found in the mouth. The bacteria found in plaque can secrete acids, enzymes and microtoxins which can cause caries, oral malodor and periodontal diseases such as gingivitis. It has been discovered that the compositions of the present invention possess a unique ability to form a concentrated and aesthetically pleasing mouthrinse. This invention provides a
15 system by which, upon dilution, relatively low concentrations of germ-killing antimicrobials can be efficiently delivered to the oral cavity. In combination with the delivery of the antimicrobial, it has also been discovered this mechanism efficiently delivers a flavoring agent. This discovery therefore provides, without non-cationic surfactants, excellent taste and breath refreshment, and also efficient delivery of
20 antimicrobial agents providing effective germ killing activity, thereby promoting oral health.

 The use of mouthrinses to reduce or eliminate the bacterial flora of the oral cavity has been recognized for some time. Examples of previous references include: U.S. Patent 4,994,262, February 19, 1991 to Charbonneau et al.; U.S. Patent
25 4,923,685, May 8, 1990 to Wuelknitz et al.; U.S. Patent 4,839,158, June 13, 1989 to Michaels; U.S. Patent 4,824,661, April 25, 1989 to Wagner; U.S. Patent 4,719,100, January 12, 1988 to Frosch; U.S. Patent 4,716,035, December 29, 1987 to Sampathkumar; U.S. Patent 4,606,911, August 19, 1986 to Hayashi et al.; U.S. Patent 4,525,343, June 25, 1985 to Raaf; U.S. Patent 4,323,551, April 6, 1982 to
30 Parran, Jr.; U.S. Patent 4,312,889, January 26, 1982 to Melsheimer; U.S. Patent 4,152,418, May 1, 1979 to Pader; U.S. Patent 4,082,841, April 4, 1978 to Pader; U.S. Patent 3,988,433, October 26, 1976 to Benedict; U.S. Patent 3,954,962, May 4, 1976 to Prussin; and U.S. Patent 3,560,608, February 2, 1971 to Griebstein et al.

 In addition to the compositions set forth in the above-mentioned U.S. Patents, several additional references disclose mouthrinses for use in the oral cavity.
35 See for example: Belgian Patent 776,425, published June 8, 1972 to Imperial Chemical Industries Limited; Canadian Patent 1081-127, published July 8, 1980;

Japanese Kokai 54008-713, published January 23, 1979; Japanese Kokai 49007-440, published January 23, 1974; Soviet Union Patent 874-061, published October 25, 1981 to Krasd Perfume Works, Soviet Union Patent Application 740-248, published June 6, 1980 to Mosc Svoboda Cosmetics (similar to U.S. Patent 3,591,675, July 6, 1971 to Brilliant).

While antimicrobials have long been used in oral mouthrinses, there is still a need for additional formulations which provide improved performance in combating oral disease along with increased user acceptance.

The present invention relates to compositions comprising certain solvents, cationic antimicrobials and noncationic antimicrobials solubilized into a concentrated solution which is aesthetically pleasing. This mouthrinse is diluted with water to provide a safe and effective means for reducing bacteria found in the oral cavity and further provides a signal of efficacy to users. Compared to the ready-to-use conventional mouthwashes and rinses, the antimicrobials and flavoring agents of the present invention are delivered more efficiently while employing similar concentrations.

It is therefore an object of the present invention to provide a concentrated and aesthetically pleasing mouthrinse which upon dilution delivers more effectively the antimicrobials and flavoring agents while employing concentrations of these ingredients similar to ready-to-use mouthwashes and rinses.

A further object of the present invention is to provide mouthrinse compositions which deliver improved antiplaque benefit.

Still a further object of the present invention is to provide a safe and effective means of preparing a mouthrinse from the concentrated solution.

These objects and other objects will become more apparent from the detailed description that follows.

SUMMARY OF THE INVENTION

The present invention relates to compositions of non-carbonated, concentrated, oil-in-water emulsions suitable for use as oral mouthrinses, comprising:

- (a) a safe and effective amount of a cationic antimicrobial agent;
- (b) a safe and effective amount of a water-insoluble, noncationic antimicrobial agent;
- (c) a safe and effective amount of a solvent suitable for use in the oral cavity;
- (d) a safe and effective amount of a flavoring agent; and
- (e) water

wherein the pH of the composition is from about 5 to about 8 and wherein the composition is substantially free of anionic and non-ionic surfactants and wherein

the said oil-in-water emulsion breaks upon dilution with greater than about 5% v/v of an aqueous solution. Methods of use are also disclosed.

All concentrations and ratios herein are by weight and all measurements are made at 25°C, unless otherwise specified.

DETAILED DESCRIPTION OF THE INVENTION

By "safe and effective amount" as used herein, means an amount sufficient to reduce oral bacteria and/or enhance such reduction while providing no adverse effects to the hard and soft tissues of the oral cavity.

By "substantially free of anionic surfactant" as used herein, means less than 0.05%, preferably less than 0.01% and most preferably less than 0.001% of an anionic surfactant. By "substantially free of non-ionic surfactant" as used herein, means an amount which will not substantially impair the activity of the cationic surfactant. Generally, this means the composition must contain less than about 0.5%, preferably less than 0.3% and most preferably less than 0.2% of the nonionic surfactant.

The compositions of this invention employ a cationic antimicrobial agent, a water-insoluble noncationic antimicrobial, a solvent or a mixture of solvents, a flavoring agent or mixture of flavoring agents and water. The concentrated mouthrinse is preferably clear. By "clear" as used herein does not mean colorless, but means substantially lacking the presence of particles of sufficient size to scatter visible light as detected visually.

At the time of usage, the concentrated mouthrinse is mixed with a desired amount of water. This mixing allows for phase separation immediately prior to use. Without being limited by theory, it is believed that this phase separation provides an efficient delivery of a sufficient level of antimicrobial agents, while allowing for optimal taste and aesthetics.

The amount of water added to the concentrated mouthrinse mixture must be high enough to result in the necessary phase change as described below. This phase change is conveniently observed by the user during dilution and provides a visual signal alerting the consumer the composition is ready for use.

Without being limited by theory, it is believed during dilution, as the oil phase and aqueous phase mix, the flavoring oils which are highly water-insoluble become uniformly dispersed within the water phase of the ready-to-use mouthrinse. The water-insoluble, noncationic antimicrobial of the present invention, combining with the flavor oils, is likewise dispersed throughout this phase. The cationic antimicrobials of the present invention, due to the inherent properties of both a hydrophobic and hydrophylic moiety, reside primarily at the oil-water interface.

Specifically, the hydrophobic moieties of the cationic antimicrobial reside within the dispersed oily phase of the bi-phasic mixture whereas the charged, hydrophilic moieties of the cationic antimicrobial position themselves around the surface (or oil-water interface) of the oily droplets, forming countless micellar particles. It is the formation of this biphasic mixture and, in particular, the positioning of the cationic antimicrobial at the oil-in-water interface which contributes to the efficient antimicrobial delivery of the present invention. In addition to its antimicrobial activity, the cationic antimicrobial also acts as a magnetic towing device, delivering its micellar contents, which include the water insoluble, noncationic antimicrobial(s), to the oppositely charged surfaces of the oral mucosa. This results in a more efficient delivery of the water insoluble, noncationic antimicrobial as well. Thus, while the water-insoluble, noncationic antimicrobial is not structured so as to ensure primary residence at the oil-water interface, it still enjoys the benefit.

This phase separation, where the oily phase is dispersed within the water phase of the diluted mouthrinse, remains for several hours. However, eventually the oily phase will coalesce and form a separate layer. Therefore, it is undesirable to dilute more concentrate than will be immediately used.

The pH of the present concentrated compositions range from about 5.0 to about 8.0 with the preferred pH being from about 6.5 to about 7.0 with the most preferred pH being about 6.9. The essential, as well as optional components of the compositions of the present invention are described below.

ESSENTIAL INGREDIENTS


Cationic antimicrobial agents

The cationic antimicrobials used in the compositions of the present invention may be selected from the group consisting of quaternary ammonium compounds and substituted guanidines such as chlorhexidine and the corresponding compound alexidine. Mixtures of these cationic antimicrobials may also be used in the present invention.

Antimicrobial quaternary ammonium compounds include those in which one or two of the substitutes on the quaternary nitrogen has a carbon chain length (typically alkyl group) from about 8 to about 20, typically from about 10 to about 18 carbon atoms while the remaining substitutes (typically alkyl or benzyl group) have a lower number of carbon atoms, such as from about 1 to about 7 carbon atoms, typically methyl or ethyl groups. Dodecyl trimethyl ammonium bromide, tetradecylpyridinium chloride, domiphen bromide, N-tetradecyl-4-ethyl pyridinium chloride, dodecyl dimethyl (2-phenoxyethyl) ammonium bromide, benzyl dimethylstearyl ammonium chloride, cetyl pyridinium chloride, quaternized

5-amino-1,3-bis(2-ethyl-hexyl)-5-methyl hexa hydropyrimidine, benzalkonium chloride, benzethonium chloride and methyl benzethonium chloride are exemplary of typical quaternary ammonium antimicrobial agents. Other compounds are bis[4-(R-amino)-1-pyridinium] alkanes as disclosed in U.S. Pat. No. 4,206,215, June 3, 1980 to Bailey which is incorporated herein by reference. The pyridinium compounds are the preferred quaternary ammonium compounds, the most preferred being cetylpyridinium chloride or tetradecylpyridinium chloride. Quaternary ammonium antimicrobial agents are included in the present invention at levels of about 0.05% to about 10.0%, preferably from about 0.2% to 3.0%, more preferably from about 0.5% to about 3.0% and most preferably from about 0.5% to about 2.0%.

The substituted guanidines are also suitable for use in this invention. Bisbiguanide compounds, which are preferred for use in the present invention, are those having the generic formula:



15 wherein A and A' can be either (1) a phenyl radical which optionally is substituted by an alkyl or alkoxy group containing from 1 to about 4 carbon atoms, a nitro group, or a halogen atom; (2) an alkyl group containing from about 1 to about 12 carbon atoms; or (3) alicyclic groups containing from about 4 to about 12 carbon atoms; wherein X and X' each represent an alkylene radical containing from about 1 to about 3 carbon atoms; wherein Z and Z' each can be either 0 or 1; wherein R and R' each represent either hydrogen, an alkyl radical containing from about 1 to about 12 carbon atoms, or an aralkyl radical containing from about 7 to about 12 carbon atoms; wherein n is an integer from 2 to 12 inclusive; wherein the polymethylene chain (CH₂)_n may optionally be interrupted for example by oxygen, sulfur atoms or aromatic nuclei. The water soluble salts of the above compounds are especially preferred for use herein. Suitable water soluble salts include the chloride, the fluoride, and especially the acetate salt. The preferred substituted guanidine is chlorhexidine-[1,6-di(-N<S>-pchlorophenyl-N-diguanido)-hexane]. The substituted guanidine antimicrobials are generally used in the present compositions at a level of from about 0.05% to about 3.0%, preferably from about 0.5% to about 3.0% and most preferably from about 0.5% to about 2.0%.

Water-insoluble, Noncationic Antimicrobials

The second essential component is a water-insoluble, noncationic antimicrobial. Given below are examples of water insoluble, noncationic antimicrobial agents useful to the present invention.

5 Halogenated Diphenyl Ethers

2',4,4'-trichloro-2-hydroxy-diphenyl ether (Triclosan)

2,2'-dihydroxy-5,5'-dibromo-diphenyl ether.

10 Phenolic Compounds (including phenol and its homologs, mono- and poly-alkyl and aromatic halophenols, resorcinol and its derivatives, bisphenolic compounds and halogenated salicylanilides).

Phenol and its Homologs

Phenol

	5-Methyl-2-(1-methylethyl)	- phenol (Thymol)
	2 Methyl	- Phenol
15	3 Methyl	- Phenol
	4 Methyl	- Phenol
	4 Ethyl	- Phenol
	2,4-Dimethyl	- Phenol
	2,5-Dimethyl	- Phenol
20	3,4-Dimethyl	- Phenol
	2,6-Dimethyl	- Phenol
	4-n-Propyl	- Phenol
	4-n-Butyl	- Phenol
	4-n-Amyl	- Phenol
25	4-tert-Amyl	- Phenol
	4-n-Hexyl	- Phenol
	4-n-Heptyl	- Phenol

Mono- and Poly-Alkyl and Aromatic Halophenols

	p-Chlorophenol	
30	Methyl	- p-Chlorophenol
	Ethyl	- p-Chlorophenol
	n-Propyl	- p-Chlorophenol
	n-Butyl	- p-Chlorophenol
	n-Amyl	- p-Chlorophenol
35	sec-Amyl	- p-Chlorophenol
	n-Hexyl	- p-Chlorophenol

	Cyclohexyl	- p-Chlorophenol
	n-Heptyl	- p-Chlorophenol
	n-Octyl	- p-Chlorophenol
	o-Chlorophenol	
5	Methyl	- o-Chlorophenol
	Ethyl - o-Chlorophenol	
	n-Propyl	- o-Chlorophenol
	n-Butyl	- o-Chlorophenol
	n-Amyl	- o-Chlorophenol
10	tert-Amyl	- o-Chlorophenol
	n-Hexyl	- o-Chlorophenol
	n-Heptyl	- o-Chlorophenol
	o-Benzyl	- p-Chlorophenol
	o-Benzyl-m-methyl	- p-Chlorophenol
15	o-Benzyl-m, m-dimethyl	- p-Chlorophenol
	o-Phenylethyl	- p-Chlorophenol
	o-Phenylethyl-m-methyl	- p-Chlorophenol
	3-Methyl	- p-Chlorophenol
	3,5-Dimethyl	- p-Chlorophenol
20	6-Ethyl-3-methyl	- p-Chlorophenol
	6-n-Propyl-3-methyl	- p-Chlorophenol
	6-iso-Propyl-3-methyl	- p-Chlorophenol
	2-Ethyl-3,5-dimethyl	- p-Chlorophenol
	6-sec-Butyl-3-methyl	- p-Chlorophenol
25	2-iso-Propyl-3,5-dimethyl	- p-Chlorophenol
	6-Diethylmethyl-3-methyl	- p-Chlorophenol
	6-iso-Propyl-2-ethyl-3-methyl	- p-Chlorophenol
	2-sec-Amyl-3,5-dimethyl	- p-Chlorophenol
	2-Diethylmethyl-3,5-dimethyl	- p-Chlorophenol
30	6-sec-Octyl-3-methyl	- p-Chlorophenol
	p-Bromophenol	
	Methyl	- p-Bromophenol
	Ethyl	- p-Bromophenol
	n-Propyl	- p-Bromophenol
35	n-Butyl	- p-Bromophenol
	n-Amyl	- p-Bromophenol
	sec-Amyl	- p-Bromophenol

8

	n-Hexyl	- p-Bromophenol
	cyclohexyl	- p-Bromophenol
	o-Bromophenol	
	tert-Amyl	- o-Bromophenol
5	n-Hexyl	- o-Bromophenol
	n-Propyl-m,mDimethyl	- o-Bromophenol
	2-Phenyl Phenol	
	4-Chloro-2-methyl phenol	
	4-Chloro-3-methyl phenol	
10	4-Chloro-3,5-dimethyl phenol	
	2,4-dichloro-3,5-dimethylphenol	
	3,4,5,6-terabromo-2-methylphenol	
	5-methyl-2-pentylphenol	
	4-isopropyl-3-methylphenol	
15	5-Chloro-2-hydroxydiphenylmethane	

Resorcinol and its Derivatives

	Resorcinol	
	Methyl	- Resorcinol
20	Ethyl	- Resorcinol
	n-Propyl	- Resorcinol
	n-Butyl	- Resorcinol
	n-Amyl	- Resorcinol
	n-Hexyl	- Resorcinol (n = 4, Hexylresorcinol)
25	n-Heptyl	- Resorcinol
	n-Octyl	- Resorcinol
	n-Nonyl	- Resorcinol
	Phenyl	- Resorcinol
	Benzyl	- Resorcinol
30	Phenylethyl	- Resorcinol
	Phenylpropyl	- Resorcinol
	p-Chlorobenzyl	- Resorcinol
	5-Chloro	-2,4-Dihydroxydiphenyl Methane
	4'-Chloro	-2,4-Dihydroxydiphenyl Methane
35	5-Bromo	-2,4-Dihydroxydiphenyl Methane
	4'-Bromo	-2,4-Dihydroxydiphenyl Methane

Bisphenolic Compounds

- 2,2'-methylene bis (4-chlorophenol)
 2,2'-methylene bis (3,4,6-trichlorophenol)
 2,2'-methylene bis (4-chloro-6-bromophenol)
 5 bis (2-hydroxy-3,5-dichlorophenyl) sulphide
 bis (2-hydroxy-5-chlorobenzyl) sulphide

Halogenated Salicylanilides

- 4',5-dibromosalicylanilide
 10 3,4',5-trichlorosalicylanilide
 3,4',5-tribromosalicylanilide
 2,3,3',5-tetrachlorosalicylanilide
 3,3',5-trichlorosalicylanilide
 3,5-dibromo-3'-trifluoromethyl salicylanilide
 15 5-n-octanoyl-3'-trifluoromethyl salicylanilide
 3,5-dibromo-4'-trifluoromethyl salicylanilide
 3,5-dibromo-3'-trifluoromethyl salicylanilide
 (Fluorophene)

20 Benzoic Esters

- p-Hydroxybenzoic Acid
 Methyl - p-Hydroxybenzoic Acid
 Ethyl - p-Hydroxybenzoic Acid
 Propyl - p-Hydroxybenzoic Acid
 25 Butyl - p-Hydroxybenzoic Acid

Halogenated Carbanilides

- 3,4,4'-trichlorocarbanilide
 3-trifluoromethyl-4,4'-dichlorocarbanilide
 30 3,3',4-trichlorocarbanilide

Without being limited by theory, it is believed that the unique combination of both the cationic and water-insoluble, noncationic antimicrobials delivered in the oil-in-water emulsion of the present invention provides improved antiplaque benefits. Specifically, it is believed that the water-insoluble noncationic compounds provide an access to bacterial colonies located within plaque matrices not readily available to cationic antimicrobials. The novel combination of these two classes of

35

antimicrobials, thus, results in a potent antiplaque composition delivering effective antiplaque activity regardless of the degree of existing plaque build-up.

The water-insoluble, noncationic antimicrobial is present in the oral composition prepared using the claimed method in an effective antiplaque amount, typically about 0.01-5% by weight, preferably about 0.03-1%. The antimicrobial agent is substantially water-insoluble, meaning that its solubility is less than about 1% by weight in water at 25°C and may be even less than about 0.1%. If an ionizable group is present solubility is determined at a pH at which ionization does not occur.

Solvents or Solvent System

Another essential ingredient of the composition of the present invention is a solvent or solvent system such as those described in U.S. Patent 5,141,961, August 25, 1992 to Coapman, herein incorporated by reference. The solvent(s), which constitute the bulk of the present composition act as a carrier for the flavoring oils. The solvent or solvent system solubilizes the flavoring oils in the concentrate and aids in dispersing, upon dilution with added water, all oil soluble components of the concentrated formulation thereby forming a uniformly dispersed mixture. The solvents most preferred for use in the present invention are: polyethylene glycols, propylene glycol, butylene glycol and hexylene glycol or mixtures thereof. Propylene glycol being the most preferred.

Propylene glycol is well known in the art and available from any of a number of suppliers. Propylene glycol is miscible in all proportions with water and also has the ability to dissolve the flavoring agent(s) of the present invention. Propylene glycol suitable for use in the present invention is obtainable from any number of sources such as Dow Chemical. Polyethylene glycols are also well known in the art and lower molecular weight species possess characteristics similar to propylene glycol. Polyethylene glycols suitable for use in the present invention are the polyethylene glycols having an average molecular weight of less than or equal to 600, such as PEG 300 "Carbowax" supplied by Union Carbide.

Solvents comprise from about 30% to about 90%, preferably from about 35% to about 80% and most preferably from about 45% to about 80% of the concentrated form of the mouthrinse.

Water

Water is present in the concentrated composition of the present invention. Water comprises from about 10% to about 40%, preferably from about 10% to about 30% and most preferably from about 10% to about 25% of the oral compositions described herein. These amounts of water include the free water which is added, plus

that amount which is introduced with other materials such as with sorbitol. The water, used in the present invention should preferably be deionized, distilled, free of organic impurities and bacteria and substantially free of metal ions.

Flavoring Agents

5 Another essential ingredient of the present invention is a flavoring agent or a mixture of compatible flavoring agents. Such flavoring agents are well known in the art. Suitable flavoring agents include: anise, cassia, clove, dihydroanethole, estragole, menthol, peppermint, oxanone, phenyl ethyl alcohol, sweet birch, thymol, eugenol, eucalyptol, wintergreen, spearmint, cinnamic aldehyde, menthone,
10 alpha-ionone, ethyl vanillin, limonene, isoamylacetate, benzaldehyde, ethylbutyrate and many others. In the herein described compositions the flavoring agents comprise from about 0.2% to about 9.0%, preferably from about 0.6% to about 4.0% and most preferably from about 2.0% to about 4.0% of the herein described composition.

OPTIONAL COMPONENTS

15 An optional ingredient useful in the present invention is a humectant or a mixture of compatible humectants. Humectants are well known in the art. In the present invention suitable humectants include the polyhydric alcohols such as xylitol, glycerin and sorbitol as well as other polyhydroxy alcohols and mixtures of these humectants. Although, it is feasible to use a single humectant, it is preferred to
20 incorporate a combination of humectants. Humectants provide from 0% to about 55%, and most preferably from about 15% to about 30% of the herein described invention. The preferred combination of humectants includes glycerin and sorbitol in a ratio of about 10:1 to about 1:4, and most preferably from about 3:1 to about 1:2.

Other optional components include, but are not limited to: coloring agents;
25 sweeteners, including saccharin, dextrose, levulose, cyclamate and aspartate, along with many others; buffering systems such as benzoic acid and sodium benzoate, citric acid and sodium citrate and any other buffering system compatible with the invention's herein described essential components. Another optional component of the present invention is ethyl alcohol. Ethyl alcohol provides several functions when
30 combined in the compositions of the present invention. Its inclusion can be, but is not limited to use as an additional antimicrobial or as an astringent. Ethyl alcohol can be incorporated in the present invention at a level of less than about 40%, preferably less than about 10% and most preferably in concentrations of less than 2%.

Still another optional component of the present invention is a cooling agent
35 such as those described in U.S. Patent 4,136,163, January 23, 1979, to Watson et al., U.S. Patent 4,230,668, October 28, 1980 to Rowsell et al. and U.S. Patent 4,032,661, to Rowsell et al. all herein incorporated by reference. One particularly

preferred cooling agent is N-ethyl-p-menthane-3-carboxamide (WS-3 supplied by Sterling Organics), taught by the above incorporated U.S. Patent 4,136,163.

PROCESS OF PREPARING

The present invention to be effectively used as an antimicrobial mouthrinse should be prepared by the user just prior to use by adding an aqueous solution, preferably water to the concentrated oil-in-water emulsion or by adding the concentrated oil-in-water emulsion to water. Upon dilution, the oil-in-water emulsion breaks, leaving the diluted composition cloudy (or opaque). This generally occurs with the addition to the emulsion of greater than 5% v/v, preferably from about 10% and most preferably from about 20% of an aqueous solution. Therefore, after dilution, the resulting composition is not completely transparent. This transformation can be visually observed, or can be readily measured using a spectrophotometer. Any appreciable difference in the absorbance of light as between the undiluted concentrate and the diluted concentrate signifies the interaction and diffusion of light necessary to the invention, establishing the range of "cloudiness." No additional agitation or mixing energy is required to cause rapid dispersion, forming a uniformly dispersed mixture of the compositions antimicrobial(s), flavoring oil(s) and other ingredients. The dilution of the mouthrinse concentrate requires mixing the concentrate with water in a range of ratios from about 1:1 to about 1:100, preferably from about 1:2 to about 1:50, more preferably from about 1:5 to about 1:50 and most preferably from about 1:20 to about 1:50.

COMPOSITION USE

The present invention in its method aspect involves rinsing the oral cavity with a safe and effective amount of a mouthrinse prepared by the user by diluting the herein described concentrate with a suitable amount of water. Generally, an amount of at least about 0.01 grams of the antimicrobial becomes available by diluting the concentrate as described above and is effective in eliminating or reducing the bacterial flora residing within the oral cavity.

METHOD OF MANUFACTURING

The method of manufacturing the disclosed compositions of the present invention are common in the oral products area.

The following examples further describe and demonstrate preferred embodiments within the scope of the present invention. The examples are given solely for illustration, and are not to be construed as limiting this invention as many variations thereof are possible without departing from its spirit and scope.

EXAMPLE I

A concentrated mouthrinse of the present invention is prepared by combining the following ingredients as described below. Also given is the dilution factor for diluting the concentrated composition.

5	<u>Dilution Ratio (concentrate:water) = 1:39</u>	
	Cetylpyridinium Chloride	2.000%
	Triclosan	3.0000%
	Propylene Glycol	77.0000%
	Water	11.0000%
10	Flavor	3.0000%
	WS-3*	1.0000%
	Sodium Saccharin	3.0000%

*N-ethyl-p-methane-3-carboxamide, offered by Wilkinson-Sword, Inc.

In a stainless steel or glass mixing tank containing the quantity of solvent, sequentially add the following ingredients dissolving each with agitation: flavor, cooling agent, benzoic acid, antimicrobial, humectant(s), purified water, sodium benzoate, sweetening agent and dye.

To the above concentrate a user adds 39 parts water.

The diluted composition will become cloudy signaling the user the mouthrinse is ready for use. The user then rinses the oral cavity with approximately 20 ml of the diluted composition and expels the mouthrinse. This use reduces or eliminates the bacteria found in the oral cavity, preventing gingivitis and oral calamity. Substantially similar results are achieved when the above exemplified antimicrobial agent is replaced in whole or in part with Dodecyl trimethyl ammonium bromide, tetradecylpyridinium chloride, domiphen bromide, N-tetradecyl-4-ethyl pyridinium chloride, dodecyl dimethyl (2-phenoxyethyl) ammonium bromide, benzyl dimethylstearyl ammonium chloride, cetyl pyridinium chloride, quaternized 5-amino-1,3-bis(2-ethyl-hexyl)-5-methyl hexa hydropyrimidine, benzalkonium chloride, benzethonium chloride and methyl benzethonium chloride or any of the other herein described antimicrobial agents.

EXAMPLE II

35	<u>Dilution Ratio (concentrate:water) = 1:39</u>	
	Cetylpyridinium Chloride	2.000%
	Thymol	2.0000%
	Propylene Glycol	75.0000%
	Water	14.5000%
	Flavor	3.0000%

WS-3	0.5000%
Sodium Saccharin	3.0000%

EXAMPLE III**Dilution Ratio (concentrate:water) = 1:2**

5	Cetylpyridinium Chloride	0.5000%
	Thymol	0.5000%
	Propylene Glycol	70.0000%
	Water	27.3000%
	Flavor	1.0000%
10	Sodium Saccharin	0.7000%

Examples II & III are combinations are manufactured in a manner substantially similar to Example I.

What is Claimed is:

1. A non-carbonated, concentrated, oral composition in the form of an oil-in-water emulsion comprising:
 - (a) from 0.05% to 10.0% of a cationic antimicrobial agent;
 - (b) from 0.05 to 10.0 of a water-insoluble, noncationic antimicrobial agent;
 - (c) from 30% to 90% of a solvent safe for use in the oral cavity;
 - (d) from 0.2% to 9.0% of a flavoring agent; and
 - (e) from 10% to 40% waterwherein the pH of the composition is from 5 to 8 and wherein the composition is substantially free of anionic and nonionic surfactants and characterized in that said oil-in-water emulsion breaks upon dilution with greater than 5% v/v of an aqueous solution.
2. An oral composition according to Claim 1 wherein the antimicrobial compound is selected from the quaternary ammonium antimicrobial group consisting of cetylpyridinium chloride and tetradecylpyridinium chloride and mixtures thereof.
3. An oral composition according to any one of the preceding Claims wherein the quaternary ammonium antimicrobial compound is present at a level of from 0.5% to 3.0%.
4. An oral composition according to any one of the preceding Claims wherein the water-insoluble, noncationic antimicrobial is selected from the group consisting of thymol, phenol, hexylresorcinol, and triclosan and mixtures thereof.
5. An oral composition according to any one of the preceding Claims wherein the water-insoluble, noncationic antimicrobial is triclosan.
6. An oral composition according to any one of the preceding Claims wherein the solvent is present at a level of from 40% to 80%.
7. An oral composition according to any one of the preceding Claims wherein the solvent is selected from the group consisting of propylene glycol and polyethylene glycol, butylene glycol, hexylene glycol and mixtures thereof.

8. An oral composition according to any one of the preceding Claims wherein the flavoring agent is from 0.6% to 4.0%.
9. An oral composition according to any one of the preceding Claims which additionally comprises from 5.0% to 55.0% of a humectant selected from the group consisting of glycerin and sorbitol and mixtures thereof.
10. An oral composition according to any one of the preceding Claims which additionally comprises from 0% to 20% ethyl alcohol.

INTERNATIONAL SEARCH REPORT

Intern. Appl. No.
PCT/US 94/14757

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K7/22 A61K7/16

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US,A,4 205 061 (VIDRA) 27 May 1980 see example 3 ---	1-10
A	US,A,5 236 699 (LIBIN) 17 August 1993 see the whole document ---	1-10
A	EP,A,0 150 374 (HENKEL) 7 August 1985 see example 7.1 ---	1-10
A	US,A,4 666 517 (BAKAR) 19 May 1987 see examples 1-2 ---	1-10
A	EP,A,0 373 758 (WARNER-LAMBERT COMPANY) 20 June 1990 see the whole document ---	1-10
-/--		

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *A* document member of the same patent family

Date of the actual completion of the international search

21 March 1995

Date of mailing of the international search report

31.03.95

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Fischer, J.P.

INTERNATIONAL SEARCH REPORT

Inter- national Application No
PCT/US 94/14757

C/(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 244 363 (WARNER-LAMBERT COMPANY) 4 November 1987 see the whole document ---	1-10
A	FR,A,2 207 689 (MERCK & CO.) 21 June 1974 see example 2 ---	1-10
A,P	WO,A,94 08558 (THE PROCTER & GAMBLE COMPANY) 28 April 1994 see the whole document -----	1-10

1

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 94/14757

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US-A-4205061	27-05-80	CA-A- 1126163 JP-A- 55015473	22-06-82 02-02-80
US-A-5236699	17-08-93	CA-A- 2098789 EP-A- 0577306	23-12-93 05-01-94
EP-A-0150374	07-08-85	DE-A- 3345781 CA-A- 1244352 JP-C- 1776159 JP-B- 4061846 JP-A- 60146817 US-A- 4820507	27-06-85 08-11-88 28-07-93 02-10-92 02-08-85 11-04-89
US-A-4666517	19-05-87	AT-B- 390367 AU-A- 7061187 BE-A- 1000312 CH-A- 673392 DE-A- 3708553 FR-A- 2599623 GB-A, B 2191092 JP-A- 62286917 NL-A- 8700741 SE-B- 466336 SE-A- 8701087	25-04-90 10-12-87 18-10-88 15-03-90 10-12-87 11-12-87 09-12-87 12-12-87 04-01-88 03-02-92 05-12-87
EP-A-0373758	20-06-90	US-A- 4992276 AU-B- 618154 AU-A- 4612789 CA-A- 2001824 JP-A- 2288825 JP-B- 6078219	12-02-91 12-12-91 21-06-90 14-06-90 28-11-90 05-10-94
EP-A-0244363	04-11-87	AU-B- 582047 AU-A- 7187887 JP-A- 62289511	09-03-89 05-11-87 16-12-87
FR-A-2207689	21-06-74	DE-A- 2257315 GB-A- 1365030 NL-A- 7216800	30-05-74 29-08-74 13-06-74

Information on patent family members

PCT/US 94/14757

**Patent document
cited in search report**

Publication
date

Patent family member(s)

Publication
date

WO-A-9408558

28-04-94

AU-B-

5296593

09-05-94